Janux Therapeutics, Inc. (JANX)
| Market Cap | 1.12B -24.7% |
| Revenue (ttm) | 24.00M +5,367.0% |
| Net Income | -102.59M |
| EPS | -1.64 |
| Shares Out | 61.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 242,203 |
| Open | 19.17 |
| Previous Close | 19.33 |
| Day's Range | 18.34 - 19.33 |
| 52-Week Range | 12.12 - 35.34 |
| Beta | 2.52 |
| Analysts | Strong Buy |
| Price Target | 36.24 (+97.28%) |
| Earnings Date | Aug 6, 2026 |
About JANX
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company’s clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008... [Read more]
Financial Performance
In 2025, Janux Therapeutics's revenue was $10.00 million, a decrease of -5.55% compared to the previous year's $10.59 million. Losses were -$113.63 million, 64.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for JANX stock is "Strong Buy." The 12-month stock price target is $36.24, which is an increase of 97.28% from the latest price.
News
Janux Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
Wolfe Research upgraded Janux Therapeutics (JANX) to Outperform from Peer Perform with a $23 price target The firm, whose analysis suggests potent B cell depletion and low CRS is “feasible”…
Janux Therapeutics price target lowered to $35 from $38 at Stifel
Stifel lowered the firm’s price target on Janux Therapeutics (JANX) to $35 from $38 and keeps a Buy rating on the shares.
Janux Therapeutics price target lowered to $55 from $58 at Guggenheim
Guggenheim lowered the firm’s price target on Janux Therapeutics (JANX) to $55 from $58 and keeps a Buy rating on the shares.
Janux Therapeutics reports Q2 EPS (35c), consensus (29c)
Reports Q2 revenue $10.267M, consensus $17.94M. “During the second quarter we continued to execute across our clinical portfolio while preparing for multiple upcoming milestones,” said David Campbell,...
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial r...
Janux Therapeutics Quarterly report: Q2 2026
Janux Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Janux Therapeutics Earnings release: Q2 2026
Janux Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Janux Therapeutics assumed with a Buy at Truist
Truist assumed coverage of Janux Therapeutics (JANX) with a Buy rating with a price target of $26, down from $80. Further refinement is needed to further improve tolerability and durability…
Janux Therapeutics reports departure of Chief Medical Officer
In a regulatory filing, Janux Therapeutics (JANX) disclosed that on June 23, William Go, M.D., Ph.D. departed as Chief Medical Officer of the company under circumstances that the company determined…
Janux Therapeutics price target lowered to $22 from $23 at Evercore ISI
Evercore ISI lowered the firm’s price target on Janux Therapeutics (JANX) to $22 from $23 and keeps an Outperform rating on the shares.
Janux Therapeutics price target lowered to $36 from $45 at Wedbush
Wedbush lowered the firm’s price target on Janux Therapeutics (JANX) to $36 from $45 and keeps an Outperform rating on the shares following quarterly results. The firm notes ANX-007 continues…
Janux Therapeutics price target lowered to $26 from $30 at Piper Sandler
Piper Sandler lowered the firm’s price target on Janux Therapeutics (JANX) to $26 from $30 and keeps an Overweight rating on the shares. The firm notes the company reported Q1…
Janux Therapeutics reports Q1 EPS (39c), consensus (52c)
Reports Q1 revenue $3.7M, consensus $4.7M. “Our commitment to advancing a prostate cancer franchise is demonstrated by our continued progress with JANX007, clinical initiation of JANX014, and advancem...
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial r...
Janux Therapeutics Earnings release: Q1 2026
Janux Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Janux Therapeutics Quarterly report: Q1 2026
Janux Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Janux Therapeutics price target lowered to $24 from $29 at BofA
BofA lowered the firm’s price target on Janux Therapeutics (JANX) to $24 from $29 and keeps a Buy rating on the shares. The firm increased its view of peak penetration…
Janux Therapeutics price target lowered to $28 from $50 at JonesResearch
JonesResearch lowered the firm’s price target on Janux Therapeutics (JANX) to $28 from $50 and keeps a Buy rating on the shares after the company announced the discontinuation of JANX008.
Janux Therapeutics Proxy statement: Proxy filing
Janux Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Janux Therapeutics Proxy statement: Proxy filing
Janux Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Janux Therapeutics announces discontinuation of JANX008 clinical development
Janux Therapeutics (JANX) announced that it will discontinue further clinical development of JANX008, its EGFR-targeted Tumor Activated T Cell Engager program. Following completion of the Phase 1a por...
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it ...
Janux Therapeutics downgraded to Underweight from Overweight at Barclays
Barclays analyst Etzer Darout double downgraded Janux Therapeutics (JANX) to Underweight from Overweight with a price target of $14, down from $29. The firm continues to see long-term value in…
Janux Therapeutics says first patient dosed in Phase 1 study of JANX014
Janux Therapeutics (JANX) “announced that the first patient has been dosed in a Phase 1 clinical trial of JANX014 in patients with metastatic castration-resistant prostate cancer. JANX014 is a double-...
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the f...